NAD+ Precursor Class / Sirtuin Pathway Research Compounds / Cellular Energetics Research
NAD+ Precursor Research — NMN vs NR vs Direct NAD+ Comparison
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells, essential for redox reactions in metabolism, DNA repair, and as a substrate for sirtuin (SIRT1–7) and PARP enzymes that regulate gene expression and cellular stress responses. Intracellular NAD+ concentrations decline with age across multiple tissues, which has motivated intense research into NAD+ precursor compounds as tools for studying age-associated metabolic decline. The three most-studied precursors are NMN (nicotinamide mononucleotide; CAS 1094-61-7; MW 334.22 Da), NR (nicotinamide riboside; CAS 1341-23-7; MW 254.24 Da), and direct NAD+ itself. Each enters the NAD+ biosynthesis pathway at a different point, with distinct cellular uptake mechanisms, pharmacokinetics, and tissue distribution profiles. This hub covers all three in the research context and provides a mechanistic comparison. Research use only.
Compound identity
- Name
- NAD+ Precursor Research — NMN, NR & NAD+ Comparison Hub
- Class
- NAD+ Precursor Class / Sirtuin Pathway Research Compounds / Cellular Energetics Research
- Also known as
- NAD+ precursor research, NMN vs NR, NMN NR NAD comparison, nicotinamide riboside vs NMN, NAD+ booster research, NMN research, NR NAD research, NAD+ longevity research, sirtuins NAD research, NAD+ aging research, nicotinamide mononucleotide research, NAD precursor comparison
Research context
The NAD+ biosynthesis pathway has three major entry points relevant to precursor research: (1) tryptophan → quinolinic acid → NAAD → NAD+ (the de novo pathway, dominant in liver); (2) nicotinamide → NMN → NAD+ (the salvage pathway, dominant in most tissues; niacin/nicotinamide are the original precursors); (3) NR → NMN → NAD+ (NR enters the salvage pathway one step upstream of NMN, via NRK1/2 kinases); (4) direct NAD+ — administered exogenously, must be taken up by cells via uncharacterized transporters or converted to NMN/NR extracellularly first. NMN bypasses the NRK step and enters cells via the Slc12a8 transporter (identified in murine intestine; human relevance under investigation). NR requires intracellular phosphorylation to NMN by NRK1 (ubiquitous) or NRK2 (muscle-enriched). The rate-limiting enzyme in the dominant salvage pathway is NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide → NMN.
Key published research landmarks in the NAD+ precursor field: (1) Mills et al. 2016 (Cell Metabolism) — oral NMN administration to aged mice restored NAD+ levels, mitochondrial function, and energy metabolism parameters; (2) Yoshino et al. 2011 (Cell Metabolism) — NMN administration reversed age-associated physiological declines in muscle, liver, and bone density in aged mice (Guarente lab); (3) Cantó et al. 2012 (Cell Metabolism) — oral NR administration increased NAD+ content in multiple tissues and activated SIRT1/SIRT3, improving mitochondrial function in mice; (4) Multiple human Phase I/II studies of NR (ChromaDex's Tru Niagen/NIAGEN) — Trammell et al. 2016 demonstrated oral NR increases blood NAD+ metabolome in humans; (5) Human NMN studies — Yoshino et al. 2021 (Science) demonstrated oral NMN (250 mg/day, 10 weeks) increased skeletal muscle NAD+ levels and improved insulin sensitivity in postmenopausal women with prediabetes. The NMN-vs-NR debate in the field centers on which precursor more efficiently raises intracellular NAD+ in specific tissues.
For researchers choosing between NMN, NR, and direct NAD+: the practical distinctions are (a) molecular weight/molar dosing — NR (254 Da) delivers more moles per gram than NMN (334 Da); (b) tissue targeting — NMN's Slc12a8 intestinal transporter may give it preferential gut/liver uptake in rodents; (c) stability — NMN is less stable in solution than NR (NMN degrades to nicotinamide at physiological pH); (d) direct NAD+ — larger molecule, lower bioavailability by oral route, may require IV or intranasal delivery for meaningful intracellular delivery in research settings. DMV Research carries both NMN and NR as research-grade lyophilized powders with ≥98% purity by HPLC. NAD+ direct is also available. All compounds are for in-vitro and pre-clinical research use only.
Frequently asked questions
What is the difference between NMN and NR as NAD+ precursors?+
NMN (nicotinamide mononucleotide, CAS 1094-61-7, MW 334.22 Da) and NR (nicotinamide riboside, CAS 1341-23-7, MW 254.24 Da) both raise intracellular NAD+ but enter the biosynthesis pathway at different points. NR requires phosphorylation to NMN by NRK1/2 kinases before entering the salvage pathway. NMN enters directly via the Slc12a8 transporter (identified in murine intestine). NR has more published human clinical data (NIAGEN/ChromaDex studies); NMN has comparable murine data and growing human evidence. Research use only.
How do NAD+ precursors activate sirtuins?+
Sirtuins (SIRT1–7) are NAD+-dependent deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and metabolic adaptation. Sirtuin activity is proportional to cellular NAD+ concentration — raising NAD+ via precursors (NMN, NR) increases sirtuin activity in metabolically active tissues. Key sirtuin targets: SIRT1 (nuclear, metabolic gene expression via PGC-1α, FOXO, p53), SIRT3 (mitochondrial, oxidative stress), SIRT6 (telomere maintenance, DNA repair). Research use only.
Is there human clinical evidence for NMN or NR raising NAD+ levels?+
Yes. For NR: Trammell et al. 2016 (Nature Communications) demonstrated that oral NR (1000 mg/day, 6 weeks) significantly raised blood NAD+ metabolome in healthy adults. Multiple subsequent trials confirmed NR's NAD+-raising effect in humans. For NMN: Yoshino et al. 2021 (Science) demonstrated 250 mg/day oral NMN for 10 weeks increased skeletal muscle NAD+ levels in postmenopausal prediabetic women. Both compounds have human Phase I safety data. Research use only; neither is approved as a therapeutic agent.
Why does NAD+ decline with age?+
Multiple mechanisms contribute to age-related NAD+ decline: (1) decreased NAMPT expression (the rate-limiting salvage enzyme); (2) increased CD38 NADase activity with age (CD38 degrades NAD+ as part of calcium signaling); (3) increased PARP activity (DNA damage accumulates with age, consuming more NAD+ for repair); (4) reduced mitochondrial efficiency (less demand drives less production). Research with NMN/NR aims to counteract these declines in preclinical aging models. Research use only.
Research use only
All products are intended for laboratory and research use only (RUO) and are not for human consumption, ingestion, or any in-vivo use.
The statements on this page have not been evaluated by the FDA. NAD+ Precursor Research — NMN, NR & NAD+ Comparison Hub is not intended to diagnose, treat, cure, or prevent any disease. Content is provided for laboratory research reference only.